Every stored oracle finding for this trial, including pending, dismissed, rejected, superseded, and accepted items.
NO_DECISIONDismissed100% confidenceGrok 4.20 (xAI)
Will the results be positive?
Trial NCT06790121 primary completion Feb 2026; current status active not recruiting. No public topline readout, press release, or results posted on ClinicalTrials.gov or sponsor sites as of Apr 2026. No sources frame outcomes positively or negatively; evidence incomplete.
Found Apr 6, 2026, 2:58 PMReviewed Apr 6, 2026, 3:00 PM
NO_DECISIONDismissed90% confidenceGrok 4.20 (xAI)
Will the results be positive?
Trial (NCT06790121 / DRI18252) is ongoing: Active Not Recruiting with primary completion Feb 2026. No public efficacy readout, top-line results, or sponsor statements on EASI percent change or overall outcome for this specific AD Phase 2b study found. Mentions of lunsekimig are limited to other indications (asthma PoC positive) or pipeline status without AD data.
Found Apr 6, 2026, 2:09 PMReviewed Apr 6, 2026, 2:19 PM
ClinicalTrialsclinicaltrials.govFeb 24, 2026, 12:00 AM
NCT06790121 | A Study to Investigate the Efficacy and Safety of Subcutaneous Lunsekimig (SAR443765) Compared With Placebo in Adult Participants With Moderate-to-severe Atopic Dermatitis
Active, not recruiting. Phase 2b, randomized, double-blind, placebo-controlled. Primary endpoint: percent change in EASI from baseline to Week 24. Estimated primary completion: 2026-02-12.
Sponsorsanofi.comApr 15, 2025, 12:00 AM
Press Release: Sanofi's respiratory pipeline advances with new phase 2 data for amlitelimab
Lunsekimig now targeting chronic rhinosinusitis and COPD. Readout of phase 2 study in AD anticipated in 2026; no results reported.
Sponsorsanofi.comDec 16, 2025, 12:00 AM
Year-end late-stage pipeline review - Sanofi
Phase 2 study in AD (VELVET: NCT06790121). Phase 2 study readout 1 in H1 2026 for other indications; no AD efficacy data or interpretation provided.
NO_DECISIONDismissed90% confidencemanual-chat-review
Will the results be positive?
ClinicalTrials.gov still lists this study as active not recruiting with no posted results, so there is not yet a clear public positive or negative trial readout.
Found Apr 4, 2026, 8:54 PMReviewed Apr 4, 2026, 10:32 PM
NO_DECISIONDismissed92% confidenceGPT-5.4 (OpenAI)
Will the results be positive?
No trial-specific public efficacy readout was found. The cited sources indicate NCT06790121/BRIGHTEN is an ongoing Phase 2b atopic dermatitis study, not a completed readout clearly framed as positive or negative. Without a public interpretation tied to this exact trial, outcome classification should remain no_decision.
Found Apr 3, 2026, 4:07 PMReviewed Apr 3, 2026, 4:47 PM
NO_DECISIONDismissed86% confidenceGPT-5.4 (OpenAI)
Will the results be positive?
No clear trial-specific public readout was found for NCT06790121. ClinicalTrials.gov still shows the Phase 2b AD study as active, and Sanofi’s Jan 29, 2026 pipeline materials still list NCT06790121 only as an ongoing lunsekimig AD program, without efficacy interpretation. That is insufficient to call the readout positive or negative.
Found Apr 1, 2026, 7:10 PMReviewed Apr 1, 2026, 7:16 PM